Teclison

Teclison is a biotechnology company specializing in the development of innovative cancer medicines. With a vision of assembling leading scientists and experts, Teclison is dedicated to creating groundbreaking therapies for cancer, focusing on inducing tumor necrosis and enhancing anti-tumor immunity to achieve long-term cancer remission. Their innovative drugs are designed to treat solid tumors, particularly those with a predilection for liver metastasis, including hepatocellular carcinoma and metastatic colorectal cancer.

Located at 26 Park Street, Suite 2100, Montclair, NJ 07042, US, which is the primary address, and with additional facilities at 10F., No.124, Sec. 2, Nanjing East Road, Taipei, 10489, TW, Teclison employs a novel approach using a first-in-class hypoxia-activating agent. This technology achieves long-term remission in hard-to-treat cancer cells, cancer stem cells, and tumor-promoting macrophage targets by creating a high local concentration of its compound and producing profound hypoxia exclusively within the tumor.

Teclison is committed to advancing cancer treatment and improving patient outcomes. The company is continually innovating and expanding its research to address various solid tumors with liver metastasis. We invite the manager of Teclison to create a customized and exclusive company showcase and product listing on our platform to further highlight their contributions to the field of biotechnology and oncology.